Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you provide evidence of the BS? ATL has posted legitimate data with sources and linking to the evidence. I also purchased Linda Liau's new book and she talks about it even herself. Read it directly from her mouth:
Was able to get my hands on Linda's new book. Does this sound like a failed trial to you? A lot of key information in there that is really nothing new, just another 'official' iteration of it. $NWBO pic.twitter.com/iXsLKZvADp
— KnowWhatYouHold (@KnowWhatYouHold) April 23, 2021
It's not the new/improved batch of DCVax.. it's the interactions with other drugs that will heighten the efficacy of DCVax.. ie. Keytruda, etc.
MERCK reports earnings next week; one would think if there was any significant interaction with NWBO, it would be reflected in their financial reporting. Thoughts?
https://finance.yahoo.com/news/merck-mrk-reports-next-week-163304583.html
Interesting read on MERCK.. nothing crazy but some insight into the new CEO: https://www.economist.com/business/2021/04/24/can-mercks-new-boss-maintain-the-drugmakers-winning-streak
Thanks Joey, I thought the same. I think our culture puts people like CardiB and Jake Paul on a pedestal and treats them with super stardom when it really should be people like Linda Liau who have made one in a billion level contributions to humanity. Her story is incredible too.. a female, 1st generation immigrant, the odds overcome.
Wed all be better people if we looked up to people like LL.
https://photos.app.goo.gl/ajBk1yb3bBexVQL99
Resharing in case you don't catch my updated thread!
Hi team - reposting my previous message because I foolishly didn't share the photo: https://photos.app.goo.gl/ajBk1yb3bBexVQL99
Previous Message:
Beyond the financial aspect of all of this, all I have to say is that we are all indebted to Linda Liau for her incredible work on DCVax and the impact that her work will have and continue to have on the world.
When you take a step back and think about it, she has LITERALLY saved the lives of many people that are still able to walk this planet because of her. I was laying in bed last night thinking about the impact of that and I had to get up and send her an e-mail, to which she responded first thing in the morning. We all should be so grateful for this treatment she has pioneered. Sharing the exchange below.
I thought about sharing this publicly, because I didn't want it to take away from the genuine place this came from, but I know most of you all are also in this for the right reasons and you might find it to be meaningful as well.
Beyond the financial aspect of all of this, all I have to say is that we are all indebted to Linda Liau for her incredible work on DCVax and the impact that her work will have and continue to have on the world.
When you take a step back and think about it, she has LITERALLY saved the lives of many people that are still able to walk this planet because of her. I was laying in bed last night thinking about the impact of that and I had to get up and send her an e-mail, to which she responded first thing in the morning. We all should be so grateful for this treatment she has pioneered. Sharing the exchange below.
https://photos.google.com/u/2/photo/AF1QipN9WWKxBGwzaYIx3BF2JfuCl2wk5-YGodwWkaE9
I thought about sharing this publicly, because I didn't want it to take away from the genuine place this came from, but I know most of you all are also in this for the right reasons and you might find it to be meaningful as well.
I purchased the section for 'Brain Tumor Vaccines' that she authored but it won't let me download the PDF. Opened a ticket and will keep you updated.
Jumped back on the PC so I can highlight:
Acknowledgments
The authors thank the Society for Neuro-Oncology and their Staff for their tremendous contributions to the arrangements and coordination for the meeting.
Authorship statement. Writing and editing of the original manuscript by all authors. Revision by P.C., F.C., P.B.W., M.G., M.P., R.M.P., and H.O. We declare no parts of the manuscript have been previously published or submitted concurrently to any other journal and all co-authors have read and approved of its submission to this journal.
Conflicts of interest statement. Y.C.: an inventor on a patent related to the TGF-beta CAR technology discussed in the publication. E.A.C.: currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., DNAtrix Inc., Immunomic Therapeutics, Sangamo Therapeutics, Seneca Therapeutics and has equity interest in DNAtrix, Immunomic Therapeutics, Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1 and noncoding RNAs. R.A.D.: founder, director, and/or advisor of Tvardi Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, Asylia Therapeutics, and Sporos Bioventures. B.M.E.: For Profits—Medicenna—Paid Consultant—Significant (>$20k), MedQIA, LLC—Paid Consultant, Ad Board, Neosoma—Paid Consultant, Agios Pharmaceuticals—Paid Consultant, Ad Board, Siemens—Paid Consultant, Research Grant, Ad Board, Janssen Pharmaceuticals—Research Grant, Imaging Endpoints—Paid Consultant, Kazia/Novogen—Paid Consultant, Ad Board, VBL—Research Grant, NW Biopharmaceuticals—Paid Consultant, Ad Board, Oncoceutics Inc.—Consultant, BeiGene—Consultant, BBI—Consultant, Tocagen—Consultant; Non-Profits: Global Coalition for Adaptive Research (GCAR)—Consultant, NIH/NCI Cancer Imaging Steering Committee—Paid Consultant, National Brain Tumor Society—Research Grant, American Cancer Society—Research Grant. J.R.H.: the founder and board member of the following companies: Indi Molecular, PACT Pharma, Isoplexis, and Sofie Biosciences. A.B.H.: serves on the scientific advisory board of Caris Life Science and WCG Oncology Board, he received licensing fees from Celldex Therapeutics and DNAtrix, received clinical trial funding from Merck and Celularity, and received study drug from Moleculin. N.K.: consultant for Abintus Bio, GenVivo, and SillaJen Biotherapeutics. L.M.L.: Consultant fees—JW Creagene, InSightec, Arbor Pharmaceuticals; Research grants to institution—Northwest Biotherapeutics, Merck. M.L.: Research Support—Arbor, BMS, Accuray, DNAtrix, Tocagen, Biohaven, Kyrin-Kyowa; Consultant—Tocagen, SQZ Technologies, VBI; CMO—Egret Therapeutics, Patent, Focused radiation + checkpoint inhibitors, Non-research Consultant – Stryker. E.W.N.: a co-founder, advisor, and shareholder of ImmunoScape Pte. Ltd. and an advisor for Neogene Therapeutics and Nanostring Technologies. H.O.: Consultant fees: Bristol-Myers Squibb, Agios Pharmaceuticals, Grant/Research support from: Agios Pharmaceuticals. Royalties as Inventor of: the H3.3K27M TCR, IL-13Ra2 (345-353:1A9V) peptide, and EGFRvIII-CAR for which an exclusive licensing agreement has been executed with Tmunity, Inc., Stemline, Inc., and Novartis Pharma, respectively. M.P.: reports non-financial support from Roche, personal fees and non-financial support from Bayer, personal fees from Novartis, personal fees from Apogenix, non-financial support from Pfizer, personal fees from Affiris outside the submitted work. In addition, M.P. has a patent EP2753315B1 licensed to Bayer, a patent EP2800580B1 issued, a patent US20180155403A1 pending, a patent US20180246118A1 pending, a patent US20170254803A1 pending, a patent WO2018146010A1 licensed to Bayer, a patent WO2019101643A1 licensed to Bayer, a patent WO2019101647A1 licensed to Bayer, a patent WO2019101641A1 licensed to Bayer, and a patent WO2019101642A1 licensed to Bayer. P.Y.W.: Research Support—Agios, Astra Zeneca/Medimmune, Beigene, Celgene, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Vascular Biogenics, VBI Vaccines; Advisory Board—Agios, Astra Zeneca, Bayer, Boston Pharmaceuticals, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, VBI Vaccines, Tocagen, Voyager, QED, Imvax, Elevate Bio; Speaker—Merck, Prime Oncology. All other authors declared none.
Hey guys, another really interesting breadcrumb linking NWBio/Merck.. this is a new article by which LL is a contributing author from late last month: https://academic.oup.com/neuro-oncology/article/23/3/356/6047273?login=true
Scroll down to the Acknowledgements section and find Northwest:
Acknowledgments
The authors thank the Society for Neuro-Oncology and their Staff for their tremendous contributions to the arrangements and coordination for the meeting.
Authorship statement. Writing and editing of the original manuscript by all authors. Revision by P.C., F.C., P.B.W., M.G., M.P., R.M.P., and H.O. We declare no parts of the manuscript have been previously published or submitted concurrently to any other journal and all co-authors have read and approved of its submission to this journal.
Conflicts of interest statement. Y.C.: an inventor on a patent related to the TGF-beta CAR technology discussed in the publication. E.A.C.: currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., DNAtrix Inc., Immunomic Therapeutics, Sangamo Therapeutics, Seneca Therapeutics and has equity interest in DNAtrix, Immunomic Therapeutics, Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1 and noncoding RNAs. R.A.D.: founder, director, and/or advisor of Tvardi Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, Asylia Therapeutics, and Sporos Bioventures. B.M.E.: For Profits—Medicenna—Paid Consultant—Significant (>$20k), MedQIA, LLC—Paid Consultant, Ad Board, Neosoma—Paid Consultant, Agios Pharmaceuticals—Paid Consultant, Ad Board, Siemens—Paid Consultant, Research Grant, Ad Board, Janssen Pharmaceuticals—Research Grant, Imaging Endpoints—Paid Consultant, Kazia/Novogen—Paid Consultant, Ad Board, VBL—Research Grant, NW Biopharmaceuticals—Paid Consultant, Ad Board, Oncoceutics Inc.—Consultant, BeiGene—Consultant, BBI—Consultant, Tocagen—Consultant; Non-Profits: Global Coalition for Adaptive Research (GCAR)—Consultant, NIH/NCI Cancer Imaging Steering Committee—Paid Consultant, National Brain Tumor Society—Research Grant, American Cancer Society—Research Grant. J.R.H.: the founder and board member of the following companies: Indi Molecular, PACT Pharma, Isoplexis, and Sofie Biosciences. A.B.H.: serves on the scientific advisory board of Caris Life Science and WCG Oncology Board, he received licensing fees from Celldex Therapeutics and DNAtrix, received clinical trial funding from Merck and Celularity, and received study drug from Moleculin. N.K.: consultant for Abintus Bio, GenVivo, and SillaJen Biotherapeutics. L.M.L.: Consultant fees—JW Creagene, InSightec, Arbor Pharmaceuticals; **Research grants to institution—Northwest Biotherapeutics, Merck. M.L.:** Research Support—Arbor, BMS, Accuray, DNAtrix, Tocagen, Biohaven, Kyrin-Kyowa; Consultant—Tocagen, SQZ Technologies, VBI; CMO—Egret Therapeutics, Patent, Focused radiation + checkpoint inhibitors, Non-research Consultant – Stryker. E.W.N.: a co-founder, advisor, and shareholder of ImmunoScape Pte. Ltd. and an advisor for Neogene Therapeutics and Nanostring Technologies. H.O.: Consultant fees: Bristol-Myers Squibb, Agios Pharmaceuticals, Grant/Research support from: Agios Pharmaceuticals. Royalties as Inventor of: the H3.3K27M TCR, IL-13Ra2 (345-353:1A9V) peptide, and EGFRvIII-CAR for which an exclusive licensing agreement has been executed with Tmunity, Inc., Stemline, Inc., and Novartis Pharma, respectively. M.P.: reports non-financial support from Roche, personal fees and non-financial support from Bayer, personal fees from Novartis, personal fees from Apogenix, non-financial support from Pfizer, personal fees from Affiris outside the submitted work. In addition, M.P. has a patent EP2753315B1 licensed to Bayer, a patent EP2800580B1 issued, a patent US20180155403A1 pending, a patent US20180246118A1 pending, a patent US20170254803A1 pending, a patent WO2018146010A1 licensed to Bayer, a patent WO2019101643A1 licensed to Bayer, a patent WO2019101647A1 licensed to Bayer, a patent WO2019101641A1 licensed to Bayer, and a patent WO2019101642A1 licensed to Bayer. P.Y.W.: Research Support—Agios, Astra Zeneca/Medimmune, Beigene, Celgene, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Vascular Biogenics, VBI Vaccines; Advisory Board—Agios, Astra Zeneca, Bayer, Boston Pharmaceuticals, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, VBI Vaccines, Tocagen, Voyager, QED, Imvax, Elevate Bio; Speaker—Merck, Prime Oncology. All other authors declared none.
Not that I see, but my guess is they might of intended a placeholder and may have taken it down to launch somewhere else
Hey, has anyone seen this? This looks to have been up at some point, but now it's taken down:
https://jitc.bmj.com/content/8/Suppl_3/A836.abstract
787 Phase III clinical trial to test the safety and efficacy of autologous tumor lysate-loaded dendritic cells in patients with newly diagnosed glioblastoma
M Bosch, L Liau, K Ashkan - 2020 - jitc.bmj.com
171 days ago - … Methods We conducted a randomized, double-blind, placebo-controlled international Phase 3 clinical trial with autologous tumor lysate-loaded DCs (DCVax-L) in 331 patients with histologically confirmed newly diagnosed GBM …
Doc- I'm also in NY, but I run the IT department got a major healthcare clinic in Illinois. Our urgent care business was awful in January/February. All flu (stomach/a/b) cases YoY were down 90%.
I do think it is multifold though. Masks for sure reduce the transmission, however I also think the behavior modification causeed by COVID are adding to it as well. Ie:
-people washing hands more often.
-people are leaving their house less often
-grouping up less densely as they would previously as well which i believe would have some compounding effect on the reduction of transmission.
Agreed. It is definitely encouraged by DeBlasio as well. Hands down the worst to ever hold the position. While I do not like to identify as right or left, I do hope we get a change of parties next election.. though I doubt that will happen because of how extremely liberal most of NYC is. They would rather see the place burn to the ground and continue the path its on then have a change in political parties.
Now I'm starting to understand your iHub handle a bit better BrightBoy.. "bright" answer :P
Though, I cannot wait until the day that we can stop having to constantly try and connect the dots on what makes sense.
That is absolutely absurd. If I start to hear that legislation here in NY - I will looking to leave for some nice warm weather south. Perhaps South Carolina :P
I'm on Long Island (NY) - It's not long before our leadership follows suit. NYC is reverting back to the 70s - sad to see happen.
Word to your mother on this one Swegen. Well said and couldnt agree more.
Going to leave this here for https://citywire.co.uk/funds-insider/news/woodfords-new-biotech-could-be-the-next-amgen/a785925 before bed:
I am personally thrilled. This means we do not need to wait until ASCO for the journal publication either!
Yeah, there is a movie about this, Nightcrawler that LC thinks is reality
Agreed, my point is just clarifying my understanding and hopefully helping others understand how SP is calculated
Thanks for clarification man. I do believed in the realistic approach. I do think there is potential for an unrealistic scenario to play out if this gains visibility from the white house and media.
Follow up question, the 1.5 billion would require a shareholder vote to authorize the addition 300 million shares correct? How would that work?
WOW. Perhaps one of the biggest breadcrumbs yet!
@Anders - Can you explain the 75 Billion valuation? I agree with what you said but I would genuinely like to understand how this all works. Doing some basic math, I came up with a two scenarios and laid out potential valuations:
Scenario #1: Total Outstanding Shares (4/16): 844,730,236
-Market Cap: 1,131,828,880
-Price: $1.34
Scenario #1 Share Price @ Specified Valuation:
-50 Billion: $59.19
-40 Billion: $47.34
-25 Billion: $29.59
-10 Billion: $11.84
Scenario #2: Total Authorized Shares (4/16): 1,200,000,000
-Market Cap: 1,131,828,880
-Share Price: $0.94
Scenario #2: Share Price @ Specified Valuation:
-50 Billion: $41.52
-40 Billion: $33.22
-25 Billion: $20.76
-10 Billion: $8.31
In this scenario #2, $50/share would need a valuation of 60 billion.
Thoughts anyone?
Same here! I think of him daily. I hope that guy makes it through.
Added more as well.
Another 5k shares purchased ??
Great post man. You are keying in on precisely why I'm 'all-in' (and many others) at this point. Anyone who understands the merit in what you just posted can translate that to a % of reduction in risk of a failed investment.
I appreciate exwannabe posts at this point because he continuously proves how weak the 'short' perspective is here and further drives confidence in my position. I also know that he's in a long position and secretly wants NWBO to succeed. He's a good guy under all that noise :)
Agreed. If I were to do a simple Google search on NWBO right now and didn't dig a bit deeper, I would never invest in NWBO. That is precisely because 8 out of 10 results talk about NWBO in a bad light. They talk about things like shady management team using LP unrelated Enron employment as evidence. They talk about how LP is loaning the company on 10% interest, using NWBO as a personal bank and delaying any movement forward because of it undisclosed, shady reasoning; aka FUD.
It's really sad to see. I think we'd have a much bigger system of support if it weren't for the work these shorts have done.
Dr. Bala - Try this link specifically: https://www.sciencedirect.com/science/article/pii/S1042368021000036
Let me know what you get. I get to the point where it asks me for a university affiliation.
@Dr. Bala - See my previous message here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162970636
I found that the content of this book is already available online if you have access (which I believe you likely do).
@reslabrat already dug in an confirmed:
There is no new information about the clinical trial. She states: "Because datalock was just recently completed at the time of this writing, the data remain blinded for this trial.
Really sad. I love this guy. Sent him some funds to help with his travel.
I can't fathom the strength it takes to be staring death right in the face and to talk about it as openly as he does. I pray that DCvax does it's job and buys him some more time. I pray for all GBM patients that DCVax is approved and is made readily available. Anyone betting against that should take a long hard look in the mirror.
Thank you very much drbala
This is a huge find! I believe this is the patent we've been following for some time now! GREAT news.
Thanks as always BB
Just spoke to her on LinkedIn - she said that she is VERY excited.
WOW! I've actually spoken to her in the past about the likelihood of NWBO's success and she was ultra confident. This is over a year ago now.